CytomX Therapeutics, Inc. (CTMX): Operating Cash Flow
-$75.59M
Year ended 2025-12-31
-$82.41M
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$75.59M | n/m | 2026-03-16, From 2025-01-01 |
| 2024-12-31 | -$86.23M | n/m | 2026-03-16, From 2024-01-01 |
| 2023-12-31 | -$56.03M | n/m | 2025-03-06, From 2023-01-01 |
| 2022-12-31 | -$110.79M | n/m | 2024-03-11, From 2022-01-01 |
| 2021-12-31 | -$119.03M | n/m | 2023-03-27, From 2021-01-01 |
| 2020-12-31 | $5.26M | n/m | 2023-03-27, From 2020-01-01 |
| 2019-12-31 | -$140.48M | n/m | 2023-03-27, From 2019-01-01 |
| 2018-12-31 | -$75.52M | n/m | 2021-02-24, From 2018-01-01 |
| 2017-12-31 | $170.37M | n/m | 2020-02-27, From 2017-01-01 |
| 2016-12-31 | -$2.03M | n/m | 2019-02-27, From 2016-01-01 |
| 2015-12-31 | -$27.41M | n/m | 2018-03-07, From 2015-01-01 |
| 2014-12-31 | $31.80M | n/m | 2017-03-02, From 2014-01-01 |
| 2013-12-31 | -$8.01M | n/a | 2016-03-07, From 2013-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | 2025-12-31 | -$75.59M | n/m |
| AbCellera Biologics Inc. (ABCL) | 2025-12-31 | -$131.29M | n/m |
| Eton Pharmaceuticals, Inc. (ETON) | 2025-12-31 | $10.52M | +986.1% |
| Bicycle Therapeutics PLC (BCYC) | 2025-12-31 | -$249.68M | n/m |
| Assembly Biosciences, Inc. (ASMB) | 2025-12-31 | -$41.09M | n/m |
| ADC Therapeutics SA (ADCT) | 2025-12-31 | -$141.17M | n/m |
| Viridian Therapeutics, Inc. (VRDN) | 2025-12-31 | -$276.39M | n/m |
| Arcturus Therapeutics Holdings Inc. (ARCT) | 2025-12-31 | -$74.27M | n/m |
| Rockwell Medical, Inc. (RMTI) | 2025-12-31 | -$659.0K | n/m |
Compare CTMX, ABCL, ETON, BCYC side by side · Screen every company in Pharmaceutical Preparations ↗